Clinical trial
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV…
NCT00005822 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005822 |
|---|---|
| Title | SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer |
| Official title | A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | doxorubicin hydrochloride, semaxanib, conventional surgery, radiation therapy, tamoxifen |
| Enrollment | 21 |
| Start date | Apr 1, 2000 |
| Primary completion | Dec 1, 2002 |
| Completion | Oct 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 11, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: